The estimated Net Worth of Martin Mackay is at least $14 million dollars as of 27 February 2017. Martin Mackay owns over 1,855 units of Charles River Laboratories International stock worth over $9,812,690 and over the last 12 years he sold CRL stock worth over $3,863,542. In addition, he makes $317,356 as Independent Director at Charles River Laboratories International.
Sign up
Martin Mackay CRL stock SEC Form 4 insiders trading
Martin has made over 13 trades of the Charles River Laboratories International stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 1,855 units of CRL stock worth $244,174 on 27 February 2017.
The largest trade he's ever made was exercising 43,500 units of Charles River Laboratories International stock on 3 August 2015 worth over $5,667,615. On average, Martin trades about 3,705 units every 36 days since 2013. As of 27 February 2017 he still owns at least 50,688 units of Charles River Laboratories International stock.
You can see the complete history of Martin Mackay stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Martin Mackay biography
Dr. Martin W. Mackay Ph.D. serves as Independent Director of the Company. Dr. Mackay is co-founder and Chief Executive Officer of Rallybio, a privately-held early-stage biotechnology company incorporated in January 2018. From May 2013 to June 2017, Dr. Mackay served as the Global Head of Research & Development at Alexion Pharmaceuticals, Inc. and from July 2010 to January 2013, Dr. Mackay served as the President of R&D at AstraZeneca PLC where he led the research and development organization and had overall accountability for delivering new products from its pipeline. Dr. Mackay's extensive experience leading research and development organizations at both global pharmaceutical and biotechnology companies provides us with a unique combination of expertise. Dr. Mackay has been a director since July 2017.
What is the salary of Martin Mackay?
As the Independent Director of Charles River Laboratories International, the total compensation of Martin Mackay at Charles River Laboratories International is $317,356. There are 14 executives at Charles River Laboratories International getting paid more, with James Foster having the highest compensation of $17,722,100.
How old is Martin Mackay?
Martin Mackay is 64, he's been the Independent Director of Charles River Laboratories International since 2017. There are 8 older and 13 younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International Inc. is Stephen Chubb, 76, who is the Independent Director.
Insiders trading at Charles River Laboratories International
Over the last 22 years, insiders at Charles River Laboratories International have traded over $220,588,205 worth of Charles River Laboratories International stock and bought 18,392 units worth $3,841,397 . The most active insiders traders include James C Foster, Richard F Wallman et David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of $2,223,188. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth $354,861.
What does Charles River Laboratories International do?
charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro
What does Charles River Laboratories International's logo look like?
Complete history of Martin Mackay stock trades at Alexion Pharmaceuticals, Charles River Laboratories International et SpringWorks Therapeutics
Charles River Laboratories International executives and stock owners
Charles River Laboratories International executives and other stock owners filed with the SEC include:
-
James Foster,
Chairman of the Board, President, Chief Executive Officer -
David Smith,
Chief Financial Officer, Corporate Executive Vice President -
James C. Foster,
Chairman, CEO & Pres -
Joseph LaPlume,
Corporate Executive Vice President, Corporate Development and Strategy -
Birgit Girshick,
Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian -
William Barbo,
Corporate Executive Vice President and Chief Commercial Officer -
David Ross Smith,
Corp. Exec. VP & CFO -
William D. Barbo,
Chief Commercial Officer & Corp. Exec. VP -
Joseph W. LaPlume,
Corp. Exec. VP of Corp. Devel. & Strategy -
Birgit Girshick,
Corp. Exec. VP & COO -
George Milne,
Lead Independent Director -
George Massaro,
Independent Director -
Robert Bertolini,
Independent Director -
Richard Reese,
Independent Director -
Richard Wallman,
Independent Director -
Martin Mackay,
Independent Director -
Deborah Kochevar,
Independent Director -
Jean-Paul Mangeolle,
Independent Director -
Stephen Chubb,
Independent Director -
Virginia Wilson,
Independent Director -
Nancy Andrews,
Independent Director -
George Llado,
Director -
Matthew L. Daniel,
Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Todd Spencer,
Corp. VP of Investor Relations -
Mark Mintz,
Corp. Sr. VP & Chief Information Officer -
Prof. Julie Frearson Ph.D.,
Corp. Sr. VP & Chief Scientific Officer -
Michael Gunnar Knell,
Corp. Sr. VP & Chief Accounting Officer -
John J Crowley,
SVP, Chief Accounting Officer -
Davide Molho,
Corporate Executive VP -
Michael Gunnar Knell,
CSVP&Chief Accounting Officer -
Craig B. Thompson,
Director -
John W Kuo,
CEVP General Counsel & CCO -
Victoria L Creamer,
EVP & Chief People Officer -
David P Johst,
Corporate Executive VP -
Jorg Geller,
OFFICERS -
Nancy Gillett,
Vice President -
Thomas F Ackerman,
Sr. Vp and CFO -
Samuel O Md Thier,
Director -
William Waltrip,
Director -
Nancy T Chang,
Director -
Christopher Berthoux,
OFFICERS -
Douglas E Rogers,
Director -
Real H Renaud,
Executive Vice President -
Brian Bathgate,
Corporate Vice President -
Joanne P Acford,
Corp. Sr VP, GC and Corp. Sec -
David J Elliott,
Officer -
Linda Mc Goldrick,
Director -
Stephanie B Wells,
Senior Vice President -
Cheri L Walker,
Corporate Senior VP -
Nicholas Ventresca,
Senior Vice President -
Michael F Ankcorn,
Corporate Sr. Vice President -
Walter S Nimmo,
Director -
S Louise Mccrary,
Director -
John C Ho,
Senior Vice President -
Alastair Stuart Mcewan,
Corporate Vice President -
John Urquhart,
Director -
Dennis R Shaughnessy,
Sr. VP Corporate Development -
Robert Cawthorn,
Director -
Flavia Pease,
Corporate Executive VP & CFO -
Shannon M Parisotto,
CEVP, Disc & Safety Assessment -
Reshema Kemps Polanco,
Director